ArticleArchivos de cardiologia de Mexico2022
Predictors in no-reflow phenomenon in acute myocardial infarction with ST-segment elevation.
Article in Archivos de cardiologia de Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 citations in OpenAlex.
- [Angiographic result with the use of adenosine before percutaneous coronary intervention in pharmacoinvasive therapy].Revista medica del Instituto Mexicano del Seguro Social · 2024Trial
- No-Reflow During Coronary Interventions: A Narrative Review.Journal of clinical medicine · 2025Review
- Bibliometric analysis of the no-reflow in ST-segment elevation myocardial infarction patients post-percutaneous coronary intervention: unveiling research trends, collaborative networks, and therapies.Journal of thoracic disease · 2025Article
- Identification and Management Strategies for Intracoronary High Thrombus Burden in Patients With STEMI: A Practical Experience and Literature Review.Reviews in cardiovascular medicine · 2025Review
- [The importance of understanding methodology in research: letter to the editor regarding the article by Godinez-Córdova et al.]Archivos de cardiologia de Mexico · 2025Article
- Predictive value of the triglyceride-glucose index for no-reflow phenomenon after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction complicated by metabolic syndrome.American journal of translational research · 2024Article
- [Clinical variables associated with no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction: Secondary analysis of the PERSTEMI I and II study].Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo-reflow (NR) phenomenon is one of the most feared complications after percutaneous coronary intervention (PCI) in the treatment of ST-segment elevation myocardial infarction (STEMI) due to its high morbidity and mortality.
objectiveTo describe the predictive factors for NR phenomenon in a group of subjects with STEMI treated with PCI.
methodOne hundred and three cases of STEMI who underwent PCI. The subjects were divided according to the presence of NR phenomenon. In a multivariate analysis age, gender, comorbidities, weight, and other clinical and laboratory parameters were studied as predictors of NR phenomenon were studied.
resultsIn this study, logistic regression analysis identified as independent factors for the development of NR phenomenon baseline TIMI flow ≤ 2 (OR 6.03; 95% CI, 0.9 to 11.8; p = 0.04), ER KDIGO ≥ 3 (OR OR 2.61; 95% CI, 1.0 to 2.4; p = 0.04).
conclusionsNR phenomenon continues to be a challenge for short and long-term morbidity and mortality in STEMI. The identified factors can be used for the stratification of cases with STEMI and risk of NR phenomenon prior to PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.